Depremler Öngörülebilir Hale Geldi: Makine Öğrenimi ile %97,97 Doğrulukla Deprem Tahmini Başarıldı
October 27, 2024 00:30 ET
|
Cemil Yavas - Industrial Engineer
STATESBORO, Ga., Oct. 27, 2024 (GLOBE NEWSWIRE) -- Georgia Southern Üniversitesi’nden Türk araştırmacı Cemil Emre Yavaş’ın da aralarında bulunduğu bir ekip, Los Angeles gibi yüksek riskli bir deprem...
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
October 26, 2024 20:15 ET
|
Biogen Inc.
The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felzartamabFelzartamab, an...
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
October 26, 2024 19:50 ET
|
Novartis Pharma AG
New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of...
TOP RANKED ROSEN LAW FIRM Encourages Coinbase Global, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – COIN
October 26, 2024 19:46 ET
|
The Rosen Law Firm PA
NEW YORK, Oct. 26, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Coinbase Global, Inc. (NASDAQ: COIN) between April 14, 2021...
Unisys Corporation Announcement: If You Have Suffered Losses in Unisys Corporation (NYSE: UIS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
October 26, 2024 19:42 ET
|
The Rosen Law Firm PA
NEW YORK, Oct. 26, 2024 (GLOBE NEWSWIRE) -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Unisys...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Bumble Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BMBL
October 26, 2024 19:36 ET
|
The Rosen Law Firm PA
NEW YORK, Oct. 26, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bumble Inc. (NASDAQ: BMBL) between November 7, 2023 and...
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
October 26, 2024 19:30 ET
|
Vera Therapeutics
Long-term improvements observed in the quartet of findings defining disease modification supports atacicept’s potential to prevent kidney failure in patients with IgAN;Long-term results from the...
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
October 26, 2024 19:23 ET
|
The Rosen Law Firm PA
NEW YORK, Oct. 26, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17,...
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Acadia Healthcare Company, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ACHC
October 26, 2024 18:19 ET
|
The Rosen Law Firm PA
NEW YORK, Oct. 26, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Acadia Healthcare Company, Inc. (NASDAQ: ACHC) between...
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
October 26, 2024 17:43 ET
|
Celldex Therapeutics, Inc.
First to demonstrate clinical benefit in patients with chronic inducible urticaria (CIndU) in large, randomized, placebo-controlled study Favorable safety and tolerability Plan to advance CIndU into...
- October 26, 2024 19:30 ET Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
- October 26, 2024 14:27 ET River Capital Limited Backs eVTOL Market to Propel Future Innovations in Urban Air Mobility